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Abstract
Cardiovascular implantable electronic devices represent important limitations to magnetic resonance imaging (MRI).
Recently, MRI-conditional dual chamber pacemakers and leads have become available. We describe a case of a
patient with neuro-sarcoidosis presenting with diplopia and hydrocephalus requiring an MRI-conditional
programmable ventriculo-peritoneal shunt, who developed complete heart block. In view of the ongoing need for
neuro-imaging, MRI-conditional dual chamber pacemaker and leads were implanted. Cardiac and brain MRI were
requested to guide immunosupression. Overall the scans demonstrated stable neurological disease, but confirmed
cardiac sarcoid, with oedema on T2 weighted images suggesting active disease and extensive sub-endocardial late
gadolinium enhancement, including the basal septum. This case illustrates why sarcoid patients who develop
bradyarrhythmias should ideally have an MRI-conditional pacing system.
Background
In the last decade, magnetic resonance imaging (MRI)
has grown dramatically. At the same time, a growing
number of patients receive cardiovascular implantable
electronic devices (pacemaker, implantable-cardioverter
defibrillators, bi-ventricular devices), a known contra-
indication to MRI. It has been estimated that a patient
with a cardiovascular electronic device has a 50-75%
lifetime requirement for MRI, which would usually be
denied [1]. A position paper from the European Heart
Rhythm Association and the Working Group on Cardio-
vascular Magnetic Resonance of the European Society of
Cardiology [1] and a scientific statement from the
American Heart Association [2] on MRI in individuals
with cardiovascular implantable electronic devices have
been published. Recently, an MRI-conditional dual
chamber pacemaker has become available and repre-
sents an important step forward to overcome one of the
major limitations of MRI.
Case presentation
A 53 year old woman presented with fatigue in com-
plete heart block. Transthoracic echocardiography was
normal. Six years previously, neuro-sarcoidosis present-
ing with diplopia and hydrocephalus had been con-
firmed by meningeal biopsy, and an MRI-conditional
programmable Ventriculo-Peritoneal shunt (PS Medical
Strata
® valve, Medtronic) had been inserted. In view of
her ongoing need for neuro-imaging, MRI-conditional
dual chamber pacemaker and leads (Advisa DR MRI™
SureScan™ with 5086 leads, Medtronic, Figure 1) were
implanted. Subsequently, in September 2010, cardiac
and brain MRI were requested to guide immunosupres-
sion. Following appropriate protocols for both MRI con-
ditional devices, interleaved pre and post contrast
cardiac, brain, and orbit MRI were performed in one
session at 1.5T. Prior to scanning, the pacemaker was
interrogated, lead integrity checked and device switched
to DOO mode at 60 bpm at 5V@1ms (from 2V@0.4ms).
Post scanning, all pacemaker parameters were unaf-
fected, and normal operation was reprogrammed. Simi-
larly, the programmable VP shunt, whose settings alter
with scanning, was reset.
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with the shunt (Figure 2), but otherwise stable intra-
cranial disease with scattered white matter lesions and
persistent dural enhancement. Cardiac MRI showed
normal LV size and systolic function with no regional
wall motion abnormalities. Metallic lead artefact was
minimised by switching standard SSFP cine sequence
(Figure 3 and additional file 1) to spoiled gradient
echo - but was not considered necessary. T2-weighted
images showed basal antero-septal oedema and there
was extensive sub-epicardial, sometimes transmural,
basal late gadolinium enhancement (Figure 4). Overall
the scans demonstrated stable neurological disease, but
confirmed cardiac sarcoid, with oedema suggesting
active disease.
Conclusions
The advent of MRI-conditional devices overcomes an
important limitation in disease management. Here, a
multidisciplinary team approach and the use and man-
agement of two concurrent MR conditional devices [3]
permitted ongoing, comprehensive assessment of multi-
system sarcoidosis [4,5]. Ironically, cardiovascular MRI
detected occult cardiac disease that suggests the possible
future requirement for an implantable-cardioverter defi-
brillator. As yet, such devices are not MRI conditional.
Figure 1 Chest radiograph (left) and magnified image (right) of pacemaker. White arrows show the MRI-conditional marker on the header
of the can (long arrow and schematic) and similar wavy line marker on the leads (short arrows).
Figure 2 Metallic artefact from the devices in the chest wall and skull.
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her device has not detected any ventricular arrhythmia.
Our case illustrates why sarcoid patients who develop
bradyarrhythmias should ideally have an MRI-condi-
tional pacing system.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompany-
ing images. A copy of the written consent is available
for review by the Editor-in-Chief of this journal.
Additional material
Additional file 1: Top: SSFP gradient echo cine (left) and spoiled
gradient echo (right) cine four chamber views. SSFP images are more
susceptible to artefacts from pacemaker leads, but image quality is good.
Bottom: SSFP-GRE short axis views, showing no regional wall motion
abnormalities.
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